Oropouche fever, a disease caused by Oropouche virus has increasingly caused international concern in recent months, drawing attention to emerging infectious diseases and arboviruses. Spread by infected biting midges and occasionally mosquitoes, this disease has primarily occurred in Central and South America, as well as the Caribbean. As more attention has been raised on this viral disease, questions around disease transmission dynamics, symptoms, and public health response continue.1
According to the Centers for Disease Control and Prevention (CDC) the most common symptoms include fever, severe headache, chills, muscle aches, and joint pain, which tend to last roughly a week.1 Unfortunately there are no vaccines or treatment modalities for Oropouche beyond supportive care.
Recent reports of viral detection in semen and reports of vertical transmission during pregnancy have prompted further analysis.2 The Lancet Infectious Diseases recently published an article on reports of vertical transmission an deaths in Brazil, pointing to the 2015-2016 Zika virus outbreak and importance of enhancing surveillance and interventions.3
The authors emphasized that roughly 5 million people across the Americas are at risk for exposure to the disease and in 2023, there was a significant surge in cases – only 261 cases were reported between 2015-2022, but in 2023 there were 831 and then by August 6, 2024, 7,497 cases were identified. Moreover, two fatalities were confirmed in younger women and in August 2024, the first documented case of vertical transmission was identified, resulting in fetal death.